Gastrointestinal stromal tumors, version 2.2014.

J Natl Compr Canc Netw

From Fox Chase Cancer Center; Huntsman Cancer Institute at the University of Utah; The University of Texas MD Anderson Cancer Center; UC San Diego Moores Cancer Center; Moffitt Cancer Center; Memorial Sloan-Kettering Cancer Center; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; Massachusetts General Hospital Cancer Center; Stanford Cancer Institute; Dana-Farber/Brigham and Women's Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; Roswell Park Cancer Institute; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; UCSF Helen Diller Family Comprehensive Cancer Center; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; City of Hope Comprehensive Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; Duke Cancer Institute; University of Michigan Comprehensive Cancer Center; Vanderbilt-Ingram Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; and National Comprehensive Cancer Network.

Published: June 2014

Gastrointestinal stromal tumors (GIST) are the most common soft tissue sarcoma of the gastrointestinal tract, resulting most commonly from KIT or platelet-derived growth factor receptor α (PDGFRα)-activating mutations. These NCCN Guideline Insights highlight the important updates to the NCCN Guidelines for Soft Tissue Sarcoma specific to the management of patients with GIST experiencing disease progression while on imatinib and/or sunitinib.

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2014.0080DOI Listing

Publication Analysis

Top Keywords

gastrointestinal stromal
8
stromal tumors
8
soft tissue
8
tissue sarcoma
8
tumors version
4
version 22014
4
22014 gastrointestinal
4
tumors gist
4
gist common
4
common soft
4

Similar Publications

Gastric schwannoma is a relatively rare submucosal mesenchymal tumor with low probability of metastasis and arises from Schwann cells of the gastrointestinal nervous plexus. Surgical therapy is the main treatment of gastric schwannoma with symptoms or malignant tendency. Gastroparesis is a potential complication following gastrointestinal surgery, which is a clinical syndrome caused by gastric emptying disorder and characterized by nausea, vomiting, and bloating, resulting in insufficient nutrient intake.

View Article and Find Full Text PDF

Background: This study aimed to investigate the clinical characteristics and esophageal motility of patients with gastric cardia submucosal tumors (SMTs) and the associated changes after endoscopic resection based on high-resolution impedance manometry (HRIM).

Methods: From our electronic database, we identified patients who underwent pre-operative evaluation of gastric cardia SMTs between 2015 and 2023. All patients completed standardized symptom questionnaires and underwent endoscopic ultrasonography and HRIM.

View Article and Find Full Text PDF

The variability in translational models profoundly impacts the outcomes and predictive value of preclinical studies for gastrointestinal (GI) cancer treatments. Preclinical models, including 2D cell cultures, 3D organoids, patient-derived xenografts (PDXs), and animal models, provide distinct advantages and limitations in replicating the complex tumor microenvironment (TME) of human cancers. Each model's unique biological and structural differences contribute to discrepancies in treatment responses, challenging the direct translation of experimental results to clinical settings.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!